Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
Overview
The Fidelity MSCI Health Care Index ETF (NYSEMKT:FHLC) provides broad healthcare exposure at a fraction of the cost of the State Street SPDR S&P Pharmaceuticals ETF (NYSEMKT:XPH), which targets a specific industry niche.
Investors seeking healthcare exposure must choose between broad sector coverage and targeted industry plays. While both funds operate within the same universe, they vary significantly in cost, diversification, and recent momentum. This comparison breaks down how these two popular ETFs navigate the medical landscape.
Details
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
Source
Originally published at www.fool.com.